Samir N. Parekh, MD, Icahn School of Medicine at Mount Sinai, New York City, NY, discuss scientific collaboration between COVID-19 and oncology researchers. Dr Parekh highlights differences in post-vaccination antibody levels in patients with myeloma vs healthy controls. An interesting point discussed here is the heterogeneity in antibody levels that can be attributed to the type of treatment given. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.